title: Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
abstract: We evaluated the effect of parathyroid hormone (PTH) on Wnt10b production by immune system cells in humans. We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T cells through increased production of Wnt10b. Chronic increase in PTH as in primary hyperparathyroidism does not increase Wnt10b expression.
  
  
  BACKGROUND
  The aim of this study is to assess the effect of PTH on Wnt10b production by immune system cells in humans. We assessed both the effect of intermittent PTH administration (iPTH) and of chronic PTH hypersecretion in primary hyperparathyroidism (PHP).
  
  
  METHODS
  Eighty-two women affected by post-menopausal osteoporosis were randomly assigned to treatment with calcium and vitamin D alone (22) or plus 1-84 PTH (42), or intravenous ibandronate (18). Wnt10b production by unfractioned blood nucleated cells and by T, B cells and monocytes was assessed by real-time RT-PCR and ELISA at baseline, 3, 6, 12 and 18 months of treatment. The effect of chronic elevation of PTH was evaluated in 20 patients affected by PHP at diagnosis and after surgical removal of parathyroid adenoma. WNT10b from both osteoporotic and PHP patients was compared to healthy subjects matched for age and sex.
  
  
  RESULTS
  iPTH increases Wnt10b production by T cells, whereas PHP does not. After surgical restoration of normal parathyroid function, WNT10b decreases, although it is still comparable with healthy subjects' level. Thus, chronic elevation of PTH does not significantly increase WNT10b production as respect to control.
  
  
  CONCLUSIONS
  This is the first work showing the effect of both intermittent and chronic PTH increase on Wnt10b production by immune system cells. We suggest that, in humans, T cells amplified the anabolic effect of PTH on bone, by increasing Wnt10b production, which stimulates osteoblast activity.
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy. patrizia.damelio@unito.it.
authors.forename: P
authors.initials: P
authors.lastname: D'Amelio
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Sassi
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Buondonno
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Fornelli
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Spertino
authors.affiliation: CeRMS, Città della Salute e della Scienza University Hospital of Torino-Italy, Torino, Italy.
authors.forename: L
authors.initials: L
authors.lastname: D'Amico
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Marchetti
authors.affiliation: Clinical Biochemistry Laboratory, Città della Salute e della Scienza University Hospital of Torino-Italy, Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Lucchiari
authors.affiliation: CeRMS, Città della Salute e della Scienza University Hospital of Torino-Italy, Torino, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Roato
authors.affiliation: Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy.
authors.forename: G C
authors.initials: GC
authors.lastname: Isaia
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000097:blood; D000077557:Ibandronic Acid; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D013601:T-Lymphocytes / Q000378:metabolism*; D014807:Vitamin D / Q000627:therapeutic use; D051153:Wnt Proteins / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C470125:PTH protein, human; D010281:Parathyroid Hormone; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; C491119:WNT10B protein, human; D051153:Wnt Proteins; D014807:Vitamin D; D002118:Calcium; D000077557:Ibandronic Acid
keywords: Immune system; Osteoporosis; PTH; Primary hyperparathyroidism; T cells; Wnt10b